Format

Send to

Choose Destination
See comment in PubMed Commons below
Ocul Immunol Inflamm. 2009 May-Jun;17(3):185-90. doi: 10.1080/09273940902862992.

Mycophenolate mofetil therapy for sarcoidosis-associated uveitis.

Author information

1
Massachusetts Eye Research and Surgery Institution, Cambridge, Massachusetts 02142, USA. fosters@uveitis.org

Abstract

PURPOSE:

To evaluate the control of ocular inflammation and the steroid sparing effect in patients with sarcoidosis-associated uveitis treated with mycophenolate mofetil (MMF).

METHODS:

Retrospective case series. All patients with a diagnosis of sarcoidosis-associated uveitis that were treated with MMF between 2005 and 2007 were identified. The dose and duration of MMF therapy and side effects were recorded.

RESULTS:

Seven patients (14 eyes) with sarcoidosis-associated uveitis were treated with MMF. The mean duration of treatment was 10 +/- 4.7 months and the average time to control uveitis was 6.7 weeks. The flare-up rate was 51.5 per 100 person-years follow-up. The best-corrected mean logMAR VA revealed improvement in all 14 eyes. The efficacy of MMF in keeping disease activity under control was maintained in 6 patients.

CONCLUSION:

These data suggest that MMF is effective in controlling sarcoidosis-related ocular inflammation, has a corticosteroid sparing effect and a manageable side-effect profile.

PMID:
19585361
DOI:
10.1080/09273940902862992
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments

    Supplemental Content

    Full text links

    Icon for Taylor & Francis
    Loading ...
    Support Center